01 August 2018
Visiongain’ has launched a new pharma Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India
This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.
The lead analyst of the report commented “Following years of medical innovation in RA treatments, payers are now prioritizing cost-saving strategies for novel drugs. Giving premium pricing for new drug entrants will also mean limiting patient access. Payers are promoting biosimilar approvals/usage and also intervening their hands-on discounts/rebates to the manufacturers. The governments/payers are also imposing various restrictions such as, prescription rules, parallel import drugs quota and drug price negotiations.
Pharma stakeholders are increasingly relying on Health Economics and Outcomes Research (HEOR) information to fully understand product value in healthcare and its potential in real-world clinical practice.”
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.